Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)
Retrieved on:
Sunday, October 2, 2022
EUA, Indonesian Ulema Council, Food, UNICEF, COVID-19, World, G20, World Health Organization, Vaccination, Pharmacy, PEHA, Certification, Laboratory, Bio Farma, Vaccine, Public health, EUL, BMGF, PATH, Emergency Use Authorization, WHO, OPV, IDX, Bill & Melinda Gates Foundation, Oral polio vaccine AIDS hypothesis, Animal, Pharmaceutical industry, Radical honesty
BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.
Key Points:
- BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.
- Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23.
- Honesti Basyir, President Director of Bio Farma, said, "UNICEF procures nOPV2 under a multilateral supply agreement as part of a global effort to prevent spread of the polio disease.
- In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like the Bill and Melinda Gates Foundation (BMGF), the PATH, and the WHO.